by Rebecca Brierley, University at Buffalo Graphical abstract. Credit: Molecular & Cellular Proteomics (2022). DOI: 10.1016/j.mcpro.2022.100409 Researchers from the University at Buffalo School of Pharmacy and Pharmaceutical Sciences recently published in Molecular & Cellular Proteomics, describing their work in identifying key metabolic regulators involved in cancer cell resistance to gemcitabine (Gem), a standard-of-care chemotherapy for pancreatic dual adenocarcinoma...
